CYMA Stock UPDATES Cymabay Therapeutics (CYMA) 6.4500 08/20/2014

New Post Public Reply Private Reply Replies (0) Message Board

Aug 20, 2014 at 6:01 AM

Cymabay Therapeutics (CYMA) 6.4500 $CYMA

CymaBay Therapeutics Announces Uplisting to the NASDAQ Capital Market Under the Symbol "CBAY"
Marketwire - Mon Jun 16, 8:02AM CDT
CymaBay Therapeutics, Inc. (OTCQB: CYMA), a clinical-stage biopharmaceutical company developing novel therapies to treat metabolic and rare diseases with high unmet need, today announced that its common stock has been approved for listing on the NASDAQ Capital Market and is expected to begin trading on Wednesday, June 18, 2014 under the symbol "CBAY". The company's common stock will continue to trade on the Over the Counter Bulletin Board, under the symbol "CYMA", until the market close on Tuesday, June 17, 2014.

CymaBay reports launch of Phase 2b study of arhalofenate in gout patients
M2 - Thu Mar 27, 5:19AM CDT
Biopharmaceutical company CymaBay Therapeutics (OTC BB:CYMA) said on Wednesday that it has randomized the first patient under its Phase 2b clinical trial of arhalofenate for for the treatment of gout, a chronic, progressive rheumatic disease.

CymaBay Initiates Arhalofenate Phase 2b Gout Study
Marketwire - Wed Mar 26, 3:21PM CDT
CymaBay Therapeutics, Inc. (OTCQB: CYMA), a biopharmaceutical company developing therapies addressing unmet medical needs in metabolic disease, today announced that it has randomized the first patient in a Phase 2b clinical trial of arhalofenate (MBX-102). Arhalofenate is a dual acting product candidate for the treatment of gout that is targeted to lower serum uric acid (sUA) and reduce the incidence of flares.

CymaBay Therapeutics Appoints Pol Boudes M.D. to Position of Chief Medical Officer
Marketwire - Mon Mar 03, 8:02AM CST
CymaBay Therapeutics, Inc. (OTCQB: CYMA), a biopharmaceutical company developing breakthrough therapies addressing unmet medical needs in metabolic diseases, today announced that Dr. Pol Boudes has joined the company as Chief Medical Officer. Dr. Boudes brings extensive clinical development experience to CymaBay, including expertise in all phases of clinical trial design and execution.

CymaBay Therapeutics to Present at Cowen and Roth Investor Conferences
Marketwire - Tue Feb 25, 8:05AM CST
CymaBay Therapeutics, Inc. (OTCQB: CYMA) today announced that Harold Van Wart, President and Chief Executive Officer, will present an overview of the company at investment conferences hosted by Cowen and Company and ROTH Capital Partners.

Mixed Dyslipidemia - Pipeline Review, H2 2013 Research Report
M2 - Thu Feb 13, 2:53AM CST
Research and Markets (http://www.researchandmarkets.com/research/85sdh6/mixed) has announced the addition of the "Mixed Dyslipidemia - Pipeline Review, H2 2013" report to their offering. 'Mixed Dyslipidemia - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Mixed Dyslipidemia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Mixed Dyslipidemia. Scope - A snapshot of the global therapeutic scenario for Mixed Dyslipidemia. - A review of the Mixed Dyslipidemia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Mixed Dyslipidemia pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Key Topics Covered: Introduction Mixed Dyslipidemia Overview Therapeutics Development Pipeline Products for Mixed Dyslipidemia - Overview Pipeline Products for Mixed Dyslipidemia - Comparative Analysis Mixed Dyslipidemia - Therapeutics under Development by Companies Mixed Dyslipidemia - Pipeline Products Glance Late Stage Products Clinical Stage Products Early Stage Products Mixed Dyslipidemia - Products under Development by Companies Mixed Dyslipidemia - Companies Involved in Therapeutics Development Mixed Dyslipidemia - Therapeutics Assessment Assessment by Monotherapy Products Assessment by Target Assessment by Mechanism of Action Assessment by Route of Administration Assessment by Molecule Type Assessment by Therapeutic Class Drug Profiles evolocumab - Drug Profile Product Description Mechanism of Action R&D Progress bococizumab - Drug Profile Product Description Mechanism of Action R&D Progress INSUPR-001 DR - Drug Profile Product Description Mechanism of Action R&D Progress MBX-8025 - Drug Profile Product Description Mechanism of Action R&D Progress PRC-4016 - Drug Profile Product Description Mechanism of Action R&D Progress CAT-2003 - Drug Profile Product Description Mechanism of Action R&D Progress MAT-9001 - Drug Profile Product Description Mechanism of Action R&D Progress Mixed Dyslipidemia - Recent Pipeline Updates Mixed Dyslipidemia - Dormant Projects Mixed Dyslipidemia - Discontinued Products Mixed Dyslipidemia - Product Development Milestones Featured News & Press Releases Appendix List of Tables List of Figures Companies Mentioned Amgen Inc. Pfizer Inc. Pronova BioPharma ASA Intas Pharmaceuticals Ltd. Catabasis Pharmaceuticals, Inc. Matinas BioPharma, Inc. CymaBay Therapeutics, Inc. For more information visit http://www.researchandmarkets.com/research/85sdh6/mixed About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

CymaBay Therapeutics Announces Listing on OTCBB and OTC Link
Marketwire - Fri Jan 24, 8:00AM CST
CymaBay Therapeutics, Inc. (OTCBB: CYMA), a biopharmaceutical company developing breakthrough therapies addressing unmet medical needs, today announced that its common stock has been cleared for quotation on the OTC Bulletin Board (OTCBB) and the OTC Market Group's OTC Link quotation system under the ticker symbol "CYMA."

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Servier's Data on Tovorafenib Shows Promise in pLGG

New Light on a Critical Challenge Talk about a fight in the dark. Pediatric low-grade glioma (pLGG) is a menace that families dread, an uphill battle with odds that feel relentless. Enter Servier and its four-year updated data on OJEMDA® (tovorafenib), a beacon of hope for kids battling these tricky brain tumors. Results, presented at the SNO meeting, are fresh off the...

HONGQI's EHS4 Launch in Europe: Bridging East and West

Revving Up a New Chapter: HONGQI in Venice There's a new player in the European automotive scene, and it's rolling in with more style than a Venetian gondola. HONGQI, a name that's been turning gears in China since '58, is packing its suitcases full of Eastern elegance and landing straight in Venice with the all-electric EHS4. On November 16, the brand is set to unveil...

WHO and RCSI Bahrain Join Forces on Health Initiatives

Forging a Healthier Pathway In a world where healthcare challenges rise faster than my blood pressure during a stock market crash, the World Health Organization (WHO) and the Royal College of Surgeons in Ireland (RCSI) – Medical University of Bahrain have inked a deal to tackle these issues head-on. The memorandum of understanding (MoU) signed on November 15, 2026,...

BETR's Slide: Investors Face Big Losses, Leadership Shift

BETR Investors Left in the Lurch It's a real trainwreck, folks. Better Home & Finance Holding Company, trading under NASDAQ:BETR, is in the spotlight for all the wrong reasons. The company expanded the class period for its investor lawsuit to include even more dates between March and August 2026, reflecting a torturous ride for shareholders. Their stock cratered by a...

Shenzhen's Vision Unveiled: APEC 2026 Promo Debut

Shenzhen's Spotlight Moment at APEC 2026 When Shenzhen announced its promotional video for the 2026 APEC Economic Leaders' Meeting, it wasn't just about standard tourism glitz. This was a show of force, a bold step onto the main stage of global politics and economics. The video's launch wasn’t merely an audio-visual delight—it staked a claim in shaping the future...

Uber Data Breach: Class Action Investigation Begins

When Tech Meets Trouble: Uber's Data Breach Picture this: the hum of Uber rides weaving through your city, drivers none the wiser that personal info has been pried from the vaults thanks to their tech partner, Fireworks AI. Uber, folks, is in hot water once again. This isn’t just another tech hiccup; it's a legal whirlwind brewing up courtesy of Edelson Lechtzin LLP, a...

Webull Faces Class Action: Key Details for Investors

What's Really Going on With Webull? When you hear there's a class-action lawsuit brewing, you know something's gone real sideways. Webull Corporation (NASDAQ: BULL) finds itself neck-deep in a securities fraud class action alleging some dicey dealings with China. If you've got skin in the game—and if you bought Webull stock between April 26, 2025, and October 6,...

EZaccessMD Data Breach: Class Action Lawsuit Looms

Data breaches are the bogeyman no one wants lurking in the shadows, and when it’s your personal info at stake, folks rightfully squirm. This recent fiasco at EZaccessMD is one of those unsettling incidents. The word on the street isn't pretty: sensitive medical data has slipped through the cracks, leaving Edelson Lechtzin LLP, a heavyweight in class action maneuvers, to...

Novo's CagriSema Trial Shows Promising Obesity Results

Novo's Latest Weight Loss Gamble Well, look what we have here. Novo Nordisk is shaking up the obesity treatment scene with some bold numbers from their REDEFINE 9 trial. The investigational CagriSema combo of amylin analog and GLP-1 receptor agonist has churned out an eyeball-popping near 21% weight loss. For context, we're staring down the barrel of numbers far meatier...

Lilly's Obesity Breakthroughs: A Step Beyond the Scale

Pushing the Boundaries of Obesity Treatment Alright, let's cut through the noise and get to what really matters here. Eli Lilly is taking on obesity treatment like it's Clash of the Titans at this year's ObesityWeek 2026 in Washington, D.C. Forget just dropping pounds—Lilly wants to reshape how we think about obesity entirely. They're not just leaning into the scale,...